Strides Pharma Science Ltd on Monday said its Singapore-based subsidiary has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc, which will strengthen the pipeline of nasal spray products across diverse therapeutic areas. Strides Pharma Global Pte, Singapore will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications, a joint statement said. The collaboration aims to accelerate affordable, high-quality medicines for patients in the US. However, it also mentioned that specific product details remain confidential at this stage. Kenox is a contract development and manufacturing company specialising in Orally Inhaled and Nasal Drug Products (OINDPs). Strides Pharma Science Executive Director Business Development Aditya Kumar said: "Weannounce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space. Nasal sprays have...

Strides Pharma Science Ltd.'s price crossed above 100Day SMA today

Strides Pharma inks collaboration with Kenox for nasal spray portfolio in the US

Business Line | 08 Sep 2025, 08:38PM

Strides Pharma Science Ltd.

08 Sep 2025, 06:22PM

894.00

0.31%

Company Update

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Strides Enters into a Strategic Product Development Partnership with Kenox to Expand Nasal Spray Portfolio for the US Market

pdf

Strides Pharma Science Ltd.

26 Aug 2025

894.00

0.31%

Company Update

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst/ Institutional Investor's Meet

pdf